News that AbbeVie’s (ABBV) Humira drug was granted FDA orphan designation for treatment of non-infectious intermediate posterior pan-uveitis or chronic non-infectious anterior uveitis moved the stock up in yesterday’s trading.
Your May $52.50 options (ABBV140517C00052500) also jumped 46.34%. Sadly, this wasn’t enough for your options to be profitable.
So sell your May $52.50 call options at a loss today before they expire worthless tomorrow.
In addition, I am recommending that you close your position in Thermo Fisher Scientific (TMO) at a slight gain as that stock has lost momentum since peaking in early March.
Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:
Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.
Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers: